CORONA Remedies Limited has clarified that the recent movement in the volume of its shares is purely market-driven. The company confirmed it is fully compliant with all disclosure obligations and currently has no undisclosed or price-sensitive information, impending announcements, or corporate actions that require sharing with the exchange. For retail...
Corona Remedies Limited officials will attend an investor conference organized by Phillip Capital PCG Group in Ahmedabad. Discussions will cover publicly available information only.
CORONA Remedies Limited held an earnings conference call to discuss the financial results for the first quarter of FY27. Management provided an overview of the company's performance, strategic initiatives, and market outlook. Following the presentation, analysts posed questions regarding various aspects of the business.
Company officials will attend investor conferences organized by Emkay Global and Equirus. These will be in-person group and one-on-one meetings in Mumbai, discussing publicly available information.
CORONA Remedies board met and approved Q1 financial results. Revenue grew 21.9% YoY to ₹422.4 Cr, PAT up 30.1% YoY to ₹60.1 Cr. The company inaugurated an EU-GMP approved Female Hormone Facility and integrated the Wokadine brand.
